Skip to main content

Volume 13 Supplement 2

IX Madrid Breast Cancer Conference

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

Introduction

Circulating endothelial cells (CECs) are shed from vessels and enter the circulation reflecting endothelial damage. Increased numbers of CECs have been documented in cancer, and appear to correlate with progression of the tumor. Bevacizumab (B) in combination with CT improves progression-free survival (PFS) of first-line treatments and may modify tumor cell intravasation and CEC/CTC levels.

Methods

Patients received B (10 mg/kg/2 weeks) combined with paclitaxel (P) 150 mg/m2 and gemcitabine (G) 2,000 mg/m2 days 1 and 15 with a cycle each 28 days of therapy, until disease progression, unacceptable toxicity or withdrawal. CTC/CECs were measured in 7.5 ml blood at baseline and after the first cycle of treatment. Enumeration was performed by the CellSearch System (Veridex).

Results

Median of follow-up was 16.28 months. Baseline CECs were available for 31 patients. Median value of baseline CECs was 130 (minimum 4 to maximum 1,407) and 60.3 (minimum 0 to maximum 349) in the second determination, P = 0.02. High levels of baseline CECs ≥200 were associated with lower PFS of 8.2 months (95% CI = 0.6 to 10.8) compared with those with <200, PFS 16.9 months (95% CI = 8.78 to NA), P = 0.003. See Figure 1. No difference was observed in OS. Fourteen patients (74%) that had stable disease/partial response decreased or maintained their CEC value. Baseline CTCs ≥5 was associated with a median PFS of 15.2 months (95% CI = 7.6 to 16.9). Twenty-two patients (92%) that had stable disease/partial response decreased or maintained their CTC value. The CTC level was not correlated with the CEC level, P = 0.74.

figure1

Figure 1

Conclusion

Our study suggests significant correlations between high levels of baseline CECs and poor prognosis. Addiction of B to first-line CT was related to a high reduction of CEC and CTC count.

Author information

Affiliations

Authors

Corresponding author

Correspondence to L Manso.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Manso, L., Ciruelos, E., Codes, M. et al. Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy. Breast Cancer Res 13, P4 (2011). https://doi.org/10.1186/bcr3025

Download citation

Keywords

  • Breast Cancer
  • Paclitaxel
  • Bevacizumab
  • Gemcitabine
  • Metastatic Breast Cancer
\